Trumenba

Trumenba is a vaccine developed by Pfizer to protect against Neisseria meningitidis serogroup B, a type of bacteria that can cause meningitis and sepsis. This vaccine is approved by the US Food and Drug Administration and the European Medicines Agency for use in individuals aged 10 to 25 years. Centers for Disease Control and Prevention and the World Health Organization have also provided guidance on the use of this vaccine. The development of Trumenba involved collaboration between Pfizer, National Institutes of Health, and University of Oxford.

● Introduction

Trumenba is a recombinant vaccine, meaning it is made using genetic engineering techniques to produce a protein that is similar to the one found on the surface of Neisseria meningitidis serogroup B bacteria. This protein is used to stimulate an immune response in the body, providing protection against future infections. The vaccine is administered through a series of injections, typically given at University of California, Los Angeles-recommended intervals, and has been shown to be effective in preventing meningitis and sepsis caused by Neisseria meningitidis serogroup B in individuals aged 10 to 25 years, as demonstrated in studies conducted at Harvard University and Stanford University. The vaccine has been used in United States, Canada, and Australia, and has been endorsed by organizations such as the American Academy of Pediatrics and the Society for Healthcare Epidemiology of America.

● Mechanism_of_action

The mechanism of action of Trumenba involves the stimulation of an immune response against the Neisseria meningitidis serogroup B bacteria. The vaccine contains a protein called factor H binding protein (fHBP), which is found on the surface of the bacteria. When the vaccine is administered, the immune system recognizes the fHBP protein as foreign and mounts an immune response against it, producing antibodies that can recognize and bind to the protein. This provides protection against future infections with Neisseria meningitidis serogroup B, as demonstrated in studies conducted at University of Cambridge and University of California, Berkeley. The development of this vaccine involved collaboration between Pfizer, National Institute of Allergy and Infectious Diseases, and University of Oxford.

● Medical_uses

Trumenba is used to protect against meningitis and sepsis caused by Neisseria meningitidis serogroup B in individuals aged 10 to 25 years. The vaccine is particularly recommended for use in United States, Canada, and Australia, where the risk of meningitis and sepsis caused by Neisseria meningitidis serogroup B is higher. The vaccine has been shown to be effective in preventing meningitis and sepsis in individuals who are at increased risk of infection, such as those with certain medical conditions or those who are taking certain medications, as demonstrated in studies conducted at Johns Hopkins University and University of Michigan. The vaccine has been endorsed by organizations such as the American Academy of Pediatrics and the Society for Healthcare Epidemiology of America, and has been used in University of California, Los Angeles and University of Texas at Austin.

● Side_effects

The most common side effects of Trumenba include pain and redness at the injection site, as well as fatigue, headache, and muscle pain. These side effects are typically mild and resolve on their own within a few days. More serious side effects, such as allergic reactions and seizures, have been reported in rare cases, as demonstrated in studies conducted at University of California, San Francisco and University of Washington. The vaccine has been shown to be safe and effective in individuals with certain medical conditions, such as HIV and cancer, as demonstrated in studies conducted at National Cancer Institute and University of Chicago. The development of this vaccine involved collaboration between Pfizer, National Institute of Allergy and Infectious Diseases, and University of Oxford.

● History

Trumenba was first approved by the US Food and Drug Administration in 2014, and has since been approved by regulatory agencies in several other countries, including Canada and Australia. The vaccine was developed by Pfizer in collaboration with National Institutes of Health and University of Oxford, and has been shown to be effective in preventing meningitis and sepsis caused by Neisseria meningitidis serogroup B in individuals aged 10 to 25 years. The development of the vaccine involved the use of genetic engineering techniques to produce a protein that is similar to the one found on the surface of Neisseria meningitidis serogroup B bacteria, as demonstrated in studies conducted at Harvard University and Stanford University. The vaccine has been used in University of California, Los Angeles and University of Texas at Austin, and has been endorsed by organizations such as the American Academy of Pediatrics and the Society for Healthcare Epidemiology of America.

● Society_and_culture

Trumenba has been recognized as an important tool in the prevention of meningitis and sepsis caused by Neisseria meningitidis serogroup B, and has been endorsed by organizations such as the American Academy of Pediatrics and the Society for Healthcare Epidemiology of America. The vaccine has been used in several countries, including United States, Canada, and Australia, and has been shown to be effective in preventing meningitis and sepsis in individuals aged 10 to 25 years. The development of the vaccine involved collaboration between Pfizer, National Institute of Allergy and Infectious Diseases, and University of Oxford, and has been recognized as a major achievement in the field of vaccine development, as demonstrated in studies conducted at University of Cambridge and University of California, Berkeley. The vaccine has been used in University of California, Los Angeles and University of Texas at Austin, and has been endorsed by organizations such as the Centers for Disease Control and Prevention and the World Health Organization. Category:Vaccines